Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» wet age-related macular degeneration
wet age-related macular degeneration
Regeneron earns mid-stage win for higher dose of Eylea, hoping to refresh its sales pitch
Endpoints
Tue, 08/24/21 - 10:51 am
Regeneron
Eylea
clinical trials
wet age-related macular degeneration
FDA starts review of Roche’s eye disease drug, setting up 2022 verdict
Pharmaforum
Thu, 07/29/21 - 10:57 pm
Roche
faricimab
bispecific antibodies
diabetic macular edema
wet age-related macular degeneration
Roche Scores Wins in AMD & COVID-19 in Big Week
BioSpace
Sun, 06/27/21 - 12:02 am
Roche
Genentech
COVID-19
wet age-related macular degeneration
Roche eyes October decision by FDA for wet AMD implant
Pharmaforum
Thu, 06/24/21 - 11:00 am
Roche
FDA
wet age-related macular degeneration
ranibizumab
Clearside’s long-acting eye project shows promise
EP Vantage
Wed, 06/16/21 - 11:48 am
Clearside Biomedical
wet age-related macular degeneration
CLS-AX
Novartis halts three trials of Beovu eye drug on safety concerns
Pharmaforum
Tue, 06/1/21 - 11:03 am
Novartis
clinical trials
Beovu
wet age-related macular degeneration
Roche eyes FDA filing after bispecific matches Eylea again
Fierce Biotech
Mon, 01/25/21 - 10:44 am
Roche
bispecifics
Regeneron
Eylea
clinical trials
faricimab
wet age-related macular degeneration
Novartis taps smartpatient for app to support wet AMD patients
Pharmaforum
Mon, 11/23/20 - 10:14 am
Novartis
wet age-related macular degeneration
digital therapeutics
MyTherapy
mobile apps
Looking for an edge in the wet AMD market, phase 3 biotech Opthea guns for $150M IPO
Fierce Biotech
Fri, 09/25/20 - 10:35 am
Opthea
IPOs
wet age-related macular degeneration
Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant
Fierce Pharma
Thu, 09/17/20 - 11:04 pm
Roche
macular degeneration
Lucentis
eye implants
wet age-related macular degeneration
FDA rejects AbbVie's eye drug, citing safety concerns
BioPharma Dive
Fri, 06/26/20 - 01:00 pm
Allergan
AbbVie
FDA
abicipar
Molecular Partners
wet age-related macular degeneration
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
Xconomy
Wed, 06/24/20 - 10:14 am
AsclepiX Therapeutics
eye disease
Eylea
Lucentis
macular edema
wet age-related macular degeneration
retinal occulsion
AXT107
Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD
BioSpace
Wed, 05/27/20 - 11:56 pm
Genentech
clinical trials
wet age-related macular degeneration
ranibizumab
Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials
Endpoints
Wed, 05/6/20 - 12:17 pm
Roche
clinical trials
bispecific antibodies
faricimab
wet age-related macular degeneration
'Lightning struck': How a safety alert shifted doctor sentiment on Novartis' Beovu
Fierce Pharma
Wed, 03/4/20 - 10:57 am
Novartis
Beovu
ASRS
occlusive vasculitis
wet age-related macular degeneration
physicians
Novartis knocked by safety scare
EP Vantage
Tue, 02/25/20 - 04:55 pm
Novartis
Regeneron
Beovu
Eylea
wet age-related macular degeneration
Novartis' hot new eye drug Beovu tied to potential vision loss: experts
Fierce Pharma
Tue, 02/25/20 - 10:02 am
Novartis
Beovu
retinal vasculitis
wet age-related macular degeneration
Eylea casts a shadow over Novartis' latest approval
Biopharma Dive
Wed, 10/9/19 - 11:04 pm
Novartis
Beovu
wet age-related macular degeneration
Regeneron
Eylea
Novartis’ new eye drug undercuts Bayer’s rival with fewer injections
Pharmaforum
Tue, 10/8/19 - 09:27 am
Novartis
brolucizumab
Bayer
Eylea
wet age-related macular degeneration
FDA
Early snapshot of Adverum's eye gene therapy sparks concern about vision loss
Endpoints
Sat, 09/14/19 - 11:25 am
Adverum Biotechnologies
wet age-related macular degeneration
gene therapy
ADVM-022
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »